Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating disease‑related splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis of JAKoMo, a prospective, non‑interventional, phase IV study in MF. Between 2012–2019 (cutoff Marc...

Descripción completa

Detalles Bibliográficos
Autores principales: Koschmieder, Steffen, Isfort, Susanne, Schulte, Clemens, Jacobasch, Lutz, Geer, Thomas, Reiser, Marcel, Koenigsmann, Michael, Heinrich, Bernhard, Wehmeyer, Jürgen, von der Heyde, Eyck, Tesch, Hans, Gröschl, Benedikt, Bachhuber, Petra, Großer, Susanne, Pahl, Heike L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640411/
https://www.ncbi.nlm.nih.gov/pubmed/37792065
http://dx.doi.org/10.1007/s00277-023-05458-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640411/
https://www.ncbi.nlm.nih.gov/pubmed/37792065
http://dx.doi.org/10.1007/s00277-023-05458-1

Ejemplares similares